SEARCH:   Advanced

Blood, 15 February 2005, Vol. 105, No. 4, pp. 1549-1551. Prepublished online as a Blood First Edition Paper on October 14, 2004; DOI 10.1182/blood-2004-08-3328. This Article Full Text (PDF) All Versions of this Article: 2004-08-3328v1 105/4/1549    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Hoppe, B. Articles by Salama, A. Search for Related Content PubMed PubMed Citation Articles by Hoppe, B. Articles by Salama, A. Related Collections Related Letter in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted August 27, 2004 Accepted October 13, 2004 Marburg I polymorphism of factor VII-activating protease is associated with idiopathic venous thromboembolism Berthold Hoppe*, Farzaneh Tolou, Hartmut Radtke, Holger Kiesewetter, Thomas Dorner, and Abdulgabar Salama Institute of Transfusion Medicine, Campus Virchow-Klinikum, Charite - Universitats Medizin Berlin, Berlin, Germany * Corresponding author; email: berthold.hoppe{at}charite.de. The factor VII-activating protease (FSAP) variant Marburg I is known to attenuate the profibrinolytic system in vitro and it was recently shown to be a significant predictor for the evolution and progression of carotid stenosis. The objective of this case-control study was to assess its role in the occurrence of venous thromboembolism (VTE). The frequency of FSAP Marburg I was significantly increased in patients with a history of VTE (17 of 213 patients, 8.0%, P = 0.014) or idiopathic VTE (12 of 103 patients, 11.7%, P = 0.002) compared to healthy controls (5 of 213 controls, 2.3%). Logistic regression analysis confirmed FSAP Marburg I to be an independent risk factor for VTE (odds ratio: 3.5, 95% confidence interval [CI]: 1.2 - 10.0) and idiopathic VTE (odds ratio: 6.2, 95% CI: 2.0 - 18.9). CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Letter in Blood Online: The Marburg I polymorphism of factor VII-activating protease is not associated with venous thrombosis Rick van Minkelen, Marieke C. H. de Visser, Hans L. Vos, Rogier M. Bertina, Frits R. Rosendaal, Berthold Hoppe, Guido A. Heymann, Hartmut Radtke, Holger Kiesewetter, Thomas Dörner, and Abdulgabar Salama Blood 2005 105: 4898-4899. [Full Text] [PDF] This article has been cited by other articles: N. L. Smith, L. A. Hindorff, S. R. Heckbert, R. N. Lemaitre, K. D. Marciante, K. Rice, T. Lumley, J. C. Bis, K. L. Wiggins, F. R. Rosendaal, et al. Association of Genetic Variations With Nonfatal Venous Thrombosis in Postmenopausal Women JAMA, February 7, 2007; 297(5): 489 - 498. [Abstract] [Full Text] [PDF] D. Sedding, J.-M. Daniel, L. Muhl, K. Hersemeyer, H. Brunsch, B. Kemkes-Matthes, R. C. Braun-Dullaeus, H. Tillmanns, T. Weimer, K. T. Preissner, et al. The G534E polymorphism of the gene encoding the factor VII-activating protease is associated with cardiovascular risk due to increased neointima formation J. Exp. Med., December 25, 2006; 203(13): 2801 - 2807. [Abstract] [Full Text] [PDF] F. Franchi, I. Martinelli, E. Biguzzi, P. Bucciarelli, and P. M. Mannucci Marburg I polymorphism of factor VII-activating protease and risk of venous thromboembolism Blood, February 15, 2006; 107(4): 1731 - 1731. [Full Text] [PDF] R. van Minkelen, M. C. H. de Visser, H. L. Vos, R. M. Bertina, F. R. Rosendaal, B. Hoppe, G. A. Heymann, H. Radtke, H. Kiesewetter, T. Dorner, et al. The Marburg I polymorphism of factor VII-activating protease is not associated with venous thrombosis Blood, June 15, 2005; 105(12): 4898 - 4899. [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020